Literature DB >> 24569821

Prevalence of gastric precancerous conditions: a systematic review and meta-analysis.

Luís Marques-Silva1, Miguel Areia, Luís Elvas, Mário Dinis-Ribeiro.   

Abstract

Several reports of estimates for precancerous conditions for gastric adenocarcinoma can be found in the current literature. Our aim was to systematically review and estimate the prevalence of gastric precancerous conditions. Four databases (PubMed, Scopus, Web of Knowledge and EBSCO Academic Search Complete) were searched for original manuscripts addressing the presence of chronic atrophic gastritis (CAG) or intestinal metaplasia (IM). Subgroup analysis was carried out on methods of diagnosis, type of population, incidence of gastric cancer, sex, Helicobacter pylori status, age and extent of conditions. Overall, 107 studies were included. The worldwide prevalence of CAG in the general population was 33% (95% confidence interval: 26-41%) when considering biopsies (n=20 912) and 24% (19-29%) if serology (n=51 886) was used, whereas IM was found in 25% (19-30%) (n=30 960). Estimates for CAG were higher in countries with a high incidence of gastric cancer (42 vs. 23%), men (32 vs. 28%), H. pylori positive (46 vs. 17%) and if aged 40 years or older (48 vs. 22%). The prevalence of extensive conditions was 16% (12-20%) for CAG and 13% (9.0-17%) for IM. When comparing countries with high versus low to moderate incidence of gastric cancer, significant differences were achieved for CAG: 27% (12-36%) versus 7.3% (5.6-9.0%). Worldwide, one-third and one-fourth of individuals may harbour CAG and IM, respectively. In countries with a high incidence of gastric cancer, the prevalence of extensive conditions may increase up to 27% and these patients represent a high-risk population to whom endoscopic surveillance should be offered according to recent guidelines.

Entities:  

Mesh:

Year:  2014        PMID: 24569821     DOI: 10.1097/MEG.0000000000000065

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  27 in total

1.  Real-time diagnosis of H. pylori infection during endoscopy: Accuracy of an innovative tool (EndoFaster).

Authors:  Guido Costamagna; Angelo Zullo; Alessandra Bizzotto; Cristiano Spada; Cesare Hassan; Maria Elena Riccioni; Clelia Marmo; Giuseppe Strangio; Teresa Antonella Di Rienzo; Giovanni Cammarota; Antonio Gasbarrini; Alessandro Repici
Journal:  United European Gastroenterol J       Date:  2015-10-13       Impact factor: 4.623

Review 2.  Anisi Stellati Fructus, a Significant Traditional Chinese Medicine (TCM) Herb and Its Bioactivity against Gastric Cancer.

Authors:  Maryam Khan; Saba Shamim
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-09       Impact factor: 2.650

Review 3.  Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance.

Authors:  Kevin Sze-Hang Liu; Irene Oi-Ling Wong; Wai K Leung
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 4.  Gastric Cancer: an Evolving Disease.

Authors:  Minkyo Song; Charles S Rabkin; M Constanza Camargo
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

5.  Evaluation of Lineage Changes in the Gastric Mucosa Following Infection With Helicobacter pylori and Specified Intestinal Flora in INS-GAS Mice.

Authors:  Carolina Pinzon-Guzman; Anne R Meyer; Rachel Wise; Eunyoung Choi; Sureshkumar Muthupalani; Timothy C Wang; James G Fox; James R Goldenring
Journal:  J Histochem Cytochem       Date:  2018-07-03       Impact factor: 2.479

6.  High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia.

Authors:  Sergejs Isajevs; Selga Savcenko; Inta Liepniece-Karele; Maria Blanca Piazuelo; Ilze Kikuste; Ivars Tolmanis; Aigars Vanags; Indra Gulbe; Linda Mezmale; Darhan Samentaev; Altynbek Tazedinov; Ramis Samsutdinov; Tatjana Belihina; Nurbek Igissinov; Marcis Leja
Journal:  Virchows Arch       Date:  2021-05-14       Impact factor: 4.064

7.  CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia.

Authors:  Athanasios Koulis; Natasha Di Costanzo; Catherine Mitchell; Stephen Lade; David Goode; Rita A Busuttil; Alex Boussioutas
Journal:  BMC Gastroenterol       Date:  2022-04-21       Impact factor: 2.847

8.  Intestinal Stem Cell Markers in the Intestinal Metaplasia of Stomach and Barrett's Esophagus.

Authors:  Bo Gun Jang; Byung Lan Lee; Woo Ho Kim
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

9.  Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk.

Authors:  Miguel Areia; Manon Cw Spaander; Ernst J Kuipers; Mário Dinis-Ribeiro
Journal:  United European Gastroenterol J       Date:  2017-07-18       Impact factor: 4.623

10.  The Transition from Gastric Intestinal Metaplasia to Gastric Cancer Involves POPDC1 and POPDC3 Downregulation.

Authors:  Rachel Gingold-Belfer; Gania Kessler-Icekson; Sara Morgenstern; Lea Rath-Wolfson; Romy Zemel; Doron Boltin; Zohar Levi; Michal Herman-Edelstein
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.